TY - JOUR

T1 - Influence of radical prostatectomy on miRNA dynamics in urine extracellular vesicles

AU - Shutko, E. V.

AU - Bryzgunova, O. E.

AU - Murina, E. A.

AU - Ostaltcev, I. A.

AU - Krasilnikov, S. E.

AU - Laktionov, P. P.

AU - Konoshenko, M. Y.

N1 - The research was carried out within the Russian state budget project to the ICBFM SB RAS (#121030200173-6 “Diagnostics and therapy of oncological diseases”)

PY - 2024/11

Y1 - 2024/11

N2 - Purpose: Cancer statistics demonstrate leading growth of prostate cancer. As a rule, radical prostatectomy (RP) is a mandatory option in the treatment of localized prostate cancer (PCa). Over 30% of patients develop biochemical resistance after the surgery and over 30% of these patients experience prostate cancer recurrence and metastasis. Currently used PCa patient's diagnostic features fail to identify PCa recurrence. To identify the risk group of PCa patients after RP we attempt to apply miRNAs which were shown as promising liquid biopsy markers for PCa diagnosis and prognosis. Materials and methods: Expression of 14 miRNAs closely involved in the development of prostate cancer from urine extracellular vesicles (uEV) of PCa patients before as well as 3, 6 and 12 months after radical prostatectomy was assessed using RT PCR and compared with their expression from uEV of healthy donors in the current study. Results: It was shown that 22 miRNA pairs prognostic ratios (MPPRs) significantly changed after radical prostatectomy. MPPRs the most promising in terms of evaluating the effectiveness of radical prostatectomy have been identified. These include two groups: MPPRs significantly changed after surgery towards that in healthy donors; and MPPRs, which divided PCa patients into two significantly different subgroups 3 or 6 months after radical prostatectomy. Conclusions: The obtained data indicate that urine EVs represent a valuable source of both MPDR and MPPR for prostate cancer.

AB - Purpose: Cancer statistics demonstrate leading growth of prostate cancer. As a rule, radical prostatectomy (RP) is a mandatory option in the treatment of localized prostate cancer (PCa). Over 30% of patients develop biochemical resistance after the surgery and over 30% of these patients experience prostate cancer recurrence and metastasis. Currently used PCa patient's diagnostic features fail to identify PCa recurrence. To identify the risk group of PCa patients after RP we attempt to apply miRNAs which were shown as promising liquid biopsy markers for PCa diagnosis and prognosis. Materials and methods: Expression of 14 miRNAs closely involved in the development of prostate cancer from urine extracellular vesicles (uEV) of PCa patients before as well as 3, 6 and 12 months after radical prostatectomy was assessed using RT PCR and compared with their expression from uEV of healthy donors in the current study. Results: It was shown that 22 miRNA pairs prognostic ratios (MPPRs) significantly changed after radical prostatectomy. MPPRs the most promising in terms of evaluating the effectiveness of radical prostatectomy have been identified. These include two groups: MPPRs significantly changed after surgery towards that in healthy donors; and MPPRs, which divided PCa patients into two significantly different subgroups 3 or 6 months after radical prostatectomy. Conclusions: The obtained data indicate that urine EVs represent a valuable source of both MPDR and MPPR for prostate cancer.

KW - Extracellular vesicles

KW - Liquid biopsy

KW - Prostate cancer

KW - Radical prostatectomy

KW - Therapy effectiveness

KW - miRNA

KW - Humans

KW - Male

KW - Prostatectomy/methods

KW - Extracellular Vesicles/metabolism

KW - MicroRNAs/urine

KW - Prostatic Neoplasms/surgery

KW - Middle Aged

KW - Aged

KW - Prognosis

KW - Biomarkers, Tumor/urine

UR - https://www.scopus.com/record/display.uri?eid=2-s2.0-85200590023&origin=inward&txGid=3a680218c85c8d9dcf1b75dee3fdc909

UR - https://www.mendeley.com/catalogue/7ce97445-7ff6-321c-8908-2ed9df779a1b/

U2 - 10.1016/j.urolonc.2024.06.017

DO - 10.1016/j.urolonc.2024.06.017

M3 - Article

C2 - 39107171

VL - 42

SP - 371.e19-371.e30

JO - Urologic Oncology: Seminars and Original Investigations

JF - Urologic Oncology: Seminars and Original Investigations

SN - 1078-1439

IS - 11

ER -